Inspire Medical Systems, Inc. $INSP Shares Sold by Janus Henderson Group PLC

Posted by Francis Steltz on Aug 11th, 2026

Janus Henderson Group PLC lessened its holdings in Inspire Medical Systems, Inc. (NYSE:INSP – Free Report) by 97.6% in the 1st quarter, Holdings Channel.com reports. The firm owned 13,451 shares of the company’s stock after selling 548,880 shares during the quarter. Janus Henderson Group PLC’s holdings in Inspire Medical Systems were worth $694,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of INSP. Royal Bank of Canada grew its holdings in Inspire Medical Systems by 16.0% in the first quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock valued at $5,220,000 after purchasing an additional 4,528 shares during the period. Integrated Wealth Concepts LLC acquired a new position in shares of Inspire Medical Systems during the 1st quarter worth approximately $524,000. Goldman Sachs Group Inc. raised its stake in shares of Inspire Medical Systems by 57.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock worth $8,190,000 after buying an additional 18,857 shares during the period. Marshall Wace LLP raised its stake in shares of Inspire Medical Systems by 3.8% during the 2nd quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock worth $2,064,000 after buying an additional 577 shares during the period. Finally, Jump Financial LLC purchased a new position in shares of Inspire Medical Systems during the 2nd quarter valued at approximately $931,000. Institutional investors and hedge funds own 94.91% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on INSP. Stifel Nicolaus set a $75.00 price target on shares of Inspire Medical Systems in a report on Tuesday, August 4th. Robert W. Baird lifted their target price on shares of Inspire Medical Systems from $54.00 to $59.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. Piper Sandler boosted their target price on shares of Inspire Medical Systems from $55.00 to $60.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. Oppenheimer upgraded shares of Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 price target for the company in a research report on Tuesday, August 4th. Finally, JPMorgan Chase & Co. raised their price target on shares of Inspire Medical Systems from $54.00 to $60.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $68.00.

View Our Latest Analysis on INSP

Inspire Medical Systems Stock Down 0.5%

Inspire Medical Systems stock opened at $59.84 on Tuesday. The company has a fifty day simple moving average of $48.02 and a 200-day simple moving average of $54.01. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of 12.95, a PEG ratio of 4.57 and a beta of 0.70. Inspire Medical Systems, Inc. has a 52-week low of $38.91 and a 52-week high of $147.03.

Inspire Medical Systems (NYSE:INSP – Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.38. The firm had revenue of $200.58 million for the quarter, compared to the consensus estimate of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The company’s revenue for the quarter was down 7.6% on a year-over-year basis. During the same period last year, the firm posted $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, research analysts anticipate that Inspire Medical Systems, Inc. will post 1.24 EPS for the current fiscal year.

Inspire Medical Systems Profile

(Free Report)

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.